



This analysis examines the new, typically innovative pharmaceutical technologies that have been submitted but do not yet make the final decision by the National Health Insurance Fund of Hungary (NHIFA) and Ministry of Human Capacities (MoHC). This special edition has been updated with the 9 month event since the [previous report](#). The previous marked in red are also represented to make the changes clear visible. The analysis focuses only on the technologies that passed the standard 90 days period and bases on the data published by the NHIFA on April 09, 2020. The validity of published data has not been investigated by Healthware.


Number of the ongoing submission procedures by reimbursement category (brands)²




In 27 (37) SKUs the exact Indications are unknown.



Average procedure length by reimbursement category (days)²



Average procedure length by ATC main groups (days)²





Number of the ongoing submission procedures by ATC5 codes²

ATC5	Name	Brands	SKUs
L01XC	Monoclonal antibodies	6	16
L01XE	Protein kinase inhibitors	6	12
V06D	Other nutrients	3	3
B01AB	Heparin group	2	7
B02BD	Blood coagulation factors	2	2
L04AC	Interleukin inhibitors	2	2
N07XX	Other nervous system drugs	2	4
A05AA	Bile acids and derivatives	1	1
A10AB	Insulins and analogues for injection, fast-acting	1	2
A10BD	Combinations of oral blood glucose lowering drugs	1	1
B01AC	Platelet aggregation inhibitors excl. heparin	1	1
B01AF	Direct factor Xa inhibitors	1	1
B02BX	Other systemic hemostatics	1	1
C03XA	Vasopressin antagonists	1	1
C09CA	Angiotensin II receptor blockers (ARBs), plain	1	2
C09DA	Angiotensin II receptor blockers (ARBs) and diuretics	1	3
C10AX	Other lipid modifying agents	1	1
D11AH	Agents for dermatitis, excluding corticosteroids	1	1
G04BX	Other urologicals	1	1
J05AX	Other direct acting antivirals	1	2
J06BB	Specific immunoglobulins	1	1
L01	ANTINEOPLASTIC AGENTS	1	2
L01CD	Taxanes	1	1
L01XX	Other antineoplastic agents	1	1
L02BB	Anti-androgens	1	1
L04AA	Selective immunosuppressants	1	2
L04AB	Tumor necrosis factor alpha (TNF-α) inhibitors	1	1
L04AX	Other immunosuppressants	1	1
M05BX	Other drugs affecting bone structure and mineralization	1	1
N02	ANALGESICS	1	1
N03AA	Barbiturates and derivatives	1	1
N03AX	Other antiepileptics	1	2
N05AE	Indole derivatives	1	1
N06BA	Centrally acting sympathomimetics	1	7
N07BA	Drug used in nicotine dependence	1	1
R03AK	Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics	1	1
S01XA	Other ophthalmologicals	1	1
V10XX	Various therapeutic radiopharmaceuticals	1	1
Total		54	91

Top 3 applicants by the number of brands and SKUs²

Top 3 ATC main group by the number of brands and SKUs²




During the NHIFA co-ordinated period, the financing structure for the technology will be determined on the basis of submitted and agreed HTA, BIA and medical considerations. The final decision is taken by a Committee coordinated by the Ministry. Actual timelines of ongoing procedures are the following:

- The average procedure time of MoHC is 512 days in case of normal submission (min-max: 312 and 827 days).
- 54 brands are waiting for ministerial decision at the moment.

- NHIFA made a preliminary decision on 7% of the normal submissions.
- The average procedure time of the analyzed products is 273 days in case of normal submission (min-max: 101 and 1155 days) and 224 days (min-max: 101 and 531 days) when simplified submission.
- The average procedure time of NHIFA is 342 days in case of normal submission (min-max: 62 and 600 days) and 174 days when simplified submission.

Typically the average waiting time is longer in case of products which claimed changes in legislation and which are innovative products with new mode of action (e.g. PCSK9 inhibitors, targeted oncology therapies, immunotherapies). The most frequent indications are the neoplastic diseases and within that the colitis ulcerosa and the non-small cell lung cancer.

With further questions, please contact us!



¹ NHIFA: National Health Insurance Fund of Hungary
² Healthware analysis based on NHIFA data
³ Standard official process period of NHIFA